Editor's note: This story was originally published Thursday, May 28.Too many red flags are flying over Hemispherx Biopharma (HEB - Get Report) to be confident in the pending U.S. approval of the company's drug for chronic fatigue syndrome.
Hemispherx's CFS Drug Is a Long Shot
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.